Skip to main content

Table 2 Demographics of study participants

From: Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation

Demographics n
No. of patients 50
No. of female patients 33
Age (years) 76.13 ± 10.08
No. of male patients 17
Age (years) 79.00 ± 7.94
No. of eyes operated total (POAG refractory to medical treatment) 50
Baseline MD (dB) total −13.31 ± 7.93
Advanced POAG, Baseline MD (dB) (n = 35) −20.50 ± 6.38
Moderate POAG, Baseline MD (dB) (n = 15) −7.37 ± 0.71
  Group A
(n)
Group B
(n)
Intergroup variable comparison
t-test, P < 0.05 (95% CI)
No. of eyes operated total 25 25 N.A
No. of pseudophakic eyes 25 25 N.A
Age (years) 77.58 ± 7.62 75.64 ± 12.61 0.88 (−6.15 to 5.32)
Baseline MD (dB) −13.15 ± 8.53 −13.47 ± 7.44 0.84 (−4.57 to 3.78)
Baseline average RNFL thickness (μm) 65.04 ± 8.03 64.54 ± 10.67 0.52 (−3.63 to 6.78)
Baseline IOP (mmHg) 23.52 ± 5.78 26.04 ± 8.76 0.26 (−1.93 to 6.77)
Baseline antiglaucoma agents 2.52 ± 0.91 2.58 ± 0.82 0.36 (−0.38 to 0.98)
Baseline DCVA (Snellen) 0.64 ± 0.24 0.58 ± 0.27 0.43 (−0.23 to 0.10)
  1. POAG primary open-angle glaucoma; IOP intraocular pressure; MD mean deviation; dB decibels; RNF retinal nerve fiber layer; CDVA corrected distance visual acuity; MMC mitomycin C; N.A not available
  2. Group A: Preserflo Microshunt with MMC 0.2 mg/ml
  3. Group B: Preserflo Microshunt with MMC 0.2 mg/ml and Ologen